Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors.

Thomas VL, Gropper SS.

Biol Trace Elem Res. 1996 Dec;55(3):297-305.

PMID:
9096856
2.
3.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
4.
5.

Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics.

Uusitupa MI, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyörälä KP, Koivistoinen PE, Lehto JT.

Am J Clin Nutr. 1983 Sep;38(3):404-10.

PMID:
6351586
6.

Effect of chromium supplementation on glucose tolerance and lipid profile.

Bahijri SM.

Saudi Med J. 2000 Jan;21(1):45-50.

PMID:
11533750
7.

Lipid profile and its relation to fasting insulin level in non-insulin dependent diabetes mellitus (NIDDM).

Uddin F, Miah AK.

Bangladesh Med Res Counc Bull. 1995 Aug;21(2):64-72.

PMID:
8815864
8.
9.

Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects.

Hermansen K, Søndergaard M, Høie L, Carstensen M, Brock B.

Diabetes Care. 2001 Feb;24(2):228-33.

PMID:
11213870
10.

Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects.

Offenbacher EG, Pi-Sunyer FX.

Diabetes. 1980 Nov;29(11):919-25.

PMID:
7000589
11.
12.

Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM.

Lee NA, Reasner CA.

Diabetes Care. 1994 Dec;17(12):1449-52.

PMID:
7882815
13.

Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.

Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G.

Diabetes Metab. 2005 Jun;31(3 Pt 1):255-60.

14.
16.

Plasma lipid abnormalities and risk factors for coronary artery disease in Japanese subjects with diabetes mellitus and glucose intolerance.

Yamada N, Yoshinaga H, Gotoda T, Harada K, Shimada M, Ohsuga J, Akanuma Y, Murase T.

Diabetes Res Clin Pract. 1994 Oct;24 Suppl:S215-20.

PMID:
7859608
17.

Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.

Hernández-Mijares A, Lluch I, Vizcarra E, Martínez-Triguero ML, Ascaso JF, Carmena R.

Nutr Metab Cardiovasc Dis. 2000 Feb;10(1):1-6.

PMID:
10812581
18.
19.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Hermann LS, Ranstam J, Vaaler S, Melander A.

Diabetes Obes Metab. 1999 Jul;1(4):227-32.

PMID:
11228758
20.

Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.

Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.

J Diabetes Complications. 2007 Jan-Feb;21(1):20-7.

PMID:
17189870

Supplemental Content

Support Center